Last reviewed · How we verify
Protonix (Pantoprazole Sodium)
Pantoprazole covalently binds (H+, K+)-ATPase at gastric parietal cells, suppressing gastric acid production.
Pantoprazole sodium for injection is a proton pump inhibitor indicated for GERD with erosive esophagitis and pathological hypersecretory conditions in adults. It covalently binds gastric (H+, K+)-ATPase with antisecretory effects exceeding 24 hours and is extensively hepatically metabolized with variable pharmacokinetics in CYP2C19 polymorphic populations. Major contraindications include rilpivirine-containing antiretrovirals and hypersensitivity to benzimidazoles, with significant interactions affecting antiretroviral and warfarin efficacy. Safety and effectiveness for upper gastrointestinal bleeding remain unestablished.
At a glance
| Generic name | Pantoprazole Sodium |
|---|---|
| Sponsor | Baxter |
| Drug class | Proton pump inhibitor (PPI) |
| Target | (H+, K+)-ATPase enzyme system |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2000 |
Mechanism of action
Pantoprazole is a proton pump inhibitor that suppresses the final step in gastric acid production by covalently binding to the (H+, K+)-ATPase enzyme system located at the secretory surface of the gastric parietal cell. This binding results in inhibition of both basal and stimulated gastric acid secretion regardless of the stimulus. The covalent binding to the (H+, K+)-ATPase produces a duration of antisecretory effect that persists longer than 24 hours across all tested doses ranging from 20 mg to 120 mg.
Approved indications
- Erosive esophagitis
- Gastric Hypersecretory Conditions
- Gastroesophageal reflux disease
- Maintenance of Healing Erosive Esophagitis
- Multiple endocrine adenomas
- Peptic ulcer
- Zollinger-Ellison syndrome
Common side effects
- Nasopharyngitis
- Haemorrhage subcutaneous
- Diarrhoea
- Epistaxis
- Contusion
- Abdominal pain upper
- Arthralgia
- Constipation
- Diabetes mellitus
- Back pain
- Dizziness
- Hypertension
Drug interactions
- Rilpivirine-containing products
- Atazanavir
- Nelfinavir
- Saquinavir
- Warfarin
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Protonix CI brief — competitive landscape report
- Protonix updates RSS · CI watch RSS
- Baxter portfolio CI